News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Akebia Therapeutics, Inc. Initiates Phase 1 Study of First-In-Class HPTPß Inhibitor for Diabetic Macular Edema


11/21/2011 8:49:44 AM

CINCINNATI--(BUSINESS WIRE)--Akebia Therapeutics, Inc., a small molecule discovery and development company focused on anemia and vascular disorders, today announced that it has dosed the first subjects in a first-in-man Phase 1 study of AKB-9778, a first-in-class human protein tyrosine phosphatase beta (HPTPß) inhibitor in development for diabetic macular edema (DME) and diabetic retinopathy (DR). AKB-9778 is designed to stabilize vessels in the back of the eye, preventing vascular leak and abnormal blood vessel growth associated with diabetic eye disease.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES